Clinical Trials Browser

Interventional × HR Positive HER2 Negative Advanced Breast Cancer × Breast × Clear all

NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 2 Recruiting

HR Positive HER2 Negative Advanced Breast Cancer

NCT05335473 2023-04-06

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase 1/2 Unknown

HR Positive HER2 Negative Advanced Breast Cancer